Drug Trial Radar · NCT04492488
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
129
Planned (sponsor's estimate)
Start
May 24, 2021
Primary completion
Oct 18, 2022
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Shanghai Miracogen Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.
Conditions
- Advanced Solid Tumors
- Advanced or Metastatic Gastric Cancer
- Advanced or Metastatic Gastroesophageal Junction Cancer
Interventions
MRG002Drug
Administrated intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD)Time frame: DLT will be evaluated during the first 21-day treatment cycle (Cycle 1)
- Recommended Phase II Dose (RP2D)Time frame: Day 1 to Day 21 of Cycle 1
- Objective Response Rate (ORR)Time frame: Baseline to study completion (24 months)
- Incidence of Adverse Events (AEs)Time frame: After signing informed consent until 45 days after the last dose of MRG002
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of California Irvine Chao Family Comprehensive Cancer Center
Orange, California
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.